Aqilion and Merck Partner to Develop Groundbreaking Treatments for Chronic Inflammation
Swedish biotech firm Aqilion has partnered with global pharmaceutical company Merck to develop new treatments for chronic inflammation and immune dysfunction. The strategic collaboration will focus on discovering and commercializing inhibitors of the TAK1 protein, which is a crucial mediator in the inflammatory process. Merck’s upfront cash payment of EUR 10 million to Aqilion is…
